1) Hori M, Matsuda T, Shibata A, et al: Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2015;45:884-91.
2) Shiba N, Shimokawa H: Prospective care of heart failure in Japan: lessons from CHART studies. EPMA J 2011;2:425-38.
3) Oikawa T, Sakata Y, Nochioka K, et al: Increased risk of cancer death in patients with chronic heart failure with a special reference to inflammation-A report from the CHART-2 Study. Int J Cardiol. 2019;290:106-112.
4) Dhorepatil A, Ball S, Ghosh RK, Kondapaneni M, et al: Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy. Am J Med 2019;132:312-24.
5) Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14.
6) Cardinale D, Colombo A, Bacchiani G, et al: Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981-8.
7) Felker GM, Thompson RE, Hare JM, et al: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84.
8) Cardinale D, Colombo A, Lamantia G, et al: Anthracycline-Induced Cardiomyopathy. Clinical Relevance and Response to Pharmacologic Therapy. J Am Coll Cardiol 2010;55:213-20.
9) Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
10) Oka T, Akazawa H, Naito AT, et al: Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure.
11) Banke A, Fosbøl EL, Møller JE, et al. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. Eur J Heart Fail 2018;20:1447-53.
12) Thavendiranathan P, Poulin F, Lim KD, at al: Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review. J Am Coll Cardiol 2014;63:2751-68.
13) Cardinale D, Sandri MT, Colombo A, et al: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-54.
14) Curigliano G, Lenihan D, Fradley M, et al: Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020:31;171-190.
15) Armenian SH, Lacchetti C, Barac A, et al: Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 2017;35:893-911.
16) Virizuela JA, García AM, de las Peñas R, et al: SEOM clinical guidelines on cardiovascular toxicity (2018). Clin Transl Oncol 2019;21:94-105.
17) Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al: 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768-2801.
18) Cai F, Luis MAF, Lin X, et al: Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment. Mol Clin Oncol 2019;11:15-23.
19) Pignatti M, Mantovani F, Bertelli L, et al: Effects of silicone expanders and implants on echocardiographic image quality after breast reconstruction. Plast Reconstr Surg 2013;132:271-8.
20) Abbasi SA, Ertel A, Shah R V, et al: Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients. J Cardiovasc Magn Reson 2013;15:89.
21) McCrohon JA, Moon JC, Prasad SK, et al: Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003;108:54-9.
22) Park SJ, Cho SW, Kim SM, et al: Assessment of Myocardial Fibrosis Using Multimodality Imaging in Severe Aortic Stenosis: Comparison with Histologic Fibrosis. JACC Cardiovasc Imaging 2019;12:109-119.
23) Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imagin. J Cardiovasc Magn Reson 2017;19:1-24.
24) Puntmann VO, Carr-White G, Jabbour A, et al: T1-Mapping and Outcome in Nonischemic Cardiomyopathy All-Cause Mortality and Heart Failure. JACC Cardiovasc Imaging 2016;9:40-50.
25) Banypersad SM, Fontana M, Maestrini V, et al: T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J 2015;36:244-51.
26) Lee H, Park JB, Yoon YE, et al: Noncontrast Myocardial T1 Mapping by Cardiac Magnetic Resonance Predicts Outcome in Patients With Aortic Stenosis. JACC Cardiovasc Imaging 2018;11:974-83.
27) Galán-Arriola C, Lobo M, Vílchez-Tschischke JP, et al: Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. J Am Coll Cardiol 2019;73:779-91.
28) Takagi H, Ota H, Umezawa R, et al: Left ventricular T1 mapping during chemotherapy- radiation therapy: Serial assessment of participants with esophageal cancer. Radiology 2018;289:347-54.
29) Nagueh SF, Smiseth OA, Appleton CP, et al: Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277-314.
30) Mitchell C, Rahko PS, Blauwet LA, et al: Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr 2019;32:1-64.
31) Messroghli DR, Greiser A, Fröhlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging 2007;26:1081-6.
32) Kellman P, Wilson JR, Xue H, et al. Extracellular volume fraction mapping in the myocardium, part 2: Initial clinical experience. J Cardiovasc Magn Reson 2012;14:1.
33) Plana JC, Galderisi M, Barac A, et al: Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063-93.
34) Breiman L, Friedman J, Stone JC, Olshen AR. Classification and regression trees. Monterey, CA: Wadsworth, Inc, 1984.
35) Zhang CJ, Pei XL, Song FY, et al. Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT. Echocardiography 2017;34:1593-600.
36) Jordan JH, Vasu S, Morgan TM, et al. Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging 2016;9:e004325.
37) Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities. J Am Coll Cardiol 2014;64:938-45.
38) Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 2015;12:547-58.
39) Kammerlander AA, Marzluf BA, Zotter-Tufaro C, et al. T1 mapping by CMR imaging from histological validation to clinical implication. JACC Cardiovasc Imaging 2016;9:14- 23.
40) Banke A, Fosbøl EL, Ewertz M, et al. Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab. JACC Heart Fail 2019;7:217-24.
41) Rosmini S, Bulluck H, Captur G, et al. Myocardial native T1 and extracellular volume with healthy ageing and gender. Eur Heart J Cardiovasc Imaging 2018;19:615-21.
42) Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013;61:77-84.
論文の公開元へ
